
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics Inc has demonstrated a robust upward trajectory in its revenue, with a year-over-year increase of 17% in Q3 FY24 and 19% in Q2 FY24, culminating in Q3 revenue of $4.1 million. The company's positive momentum is bolstered by anticipated expansions into new locations and the successful introduction of higher pricing strategies following recent FDA clearances. Furthermore, with improved revenue forecasts for FY24, now estimated at $16.3 million, Vivos Therapeutics is positioning itself toward achieving breakeven status by FY2025.
Bears say
Vivos Therapeutics Inc is facing a negative outlook as its FY24 revenue estimate has been reduced to $15.2 million from $16.3 million, indicating potential struggles in sales performance. The pro forma EPS figures are underwhelming, with negative earnings per share identified at $(0.55) and $(0.60) for recent periods, both surpassing estimates and consensus projections, raising concerns regarding profitability and operational efficiency. Additionally, the company faces significant risks including balance sheet and liquidity issues, regulatory hurdles, market competition, and challenges in commercialization and reimbursement, all of which may impede its growth trajectory and overall financial stability.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares